Stockreport

TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting [Yahoo! Finance]

TG Therapeutics, Inc.  (TGTX) 
Last tg therapeutics, inc. earnings: 11/12 07:34 am Check Earnings Report
US:NASDAQ Investor Relations: ir.tgtherapeutics.com
PDF post-marketing studies being undertaken for BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple [Read more]